

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

DELAY IN PUBLICATION OF ANNUAL RESULTS AND DESPATCH OF ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

Reference is made to the announcements of China Wah Yan Healthcare Limited (the “Company”) dated 29 March 2018 and 31 March 2019 (the “Announcements”) relating to the delay in the publication of the audited 2017 Annual Results and 2018 Annual Results. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Announcements.

On 29 March 2018 and 31 March 2019, the Company announced that it could not publish the audited 2017 Annual Results and 2018 Annual Results in light of the reasons, amongst the others, completion of the audit of the 2017 Annual Results and the 2018 Annual Results is subject to the conclusion of the Investigation. As the publication of the 2017 Annual Results and the 2018 Annual Results and the despatch of the 2017 Annual Report and the 2018 Annual Report are still pending, the announcement of the annual results (the “2019 Annual Results”) and the despatch of the annual report (the “2019 Annual Report”) of the Company for the year ended 31 December 2019 will not be ready by 31 March 2020 and 30 April 2020 respectively as required under the Listing Rules. Given the above, the date of the meeting of the Board for the considering and approving the audited 2019 Annual Results has not been fixed.

Pursuant to Rule 13.49(3) of the Listing Rules, where an issuer is unable to issue its preliminary results in accordance with Rule 13.49(1) of the Listing Rules, it must announce its results based on the financial results yet to be agreed with the auditors (so far as the information is available). After due and careful consideration, the Board is of the view that it would not be appropriate for the Company to announce its unaudited 2019 Annual Results at this stage, in particular, after considering that (i) completion and issuance of the audited 2017 Annual Results and 2018 Annual Results remain outstanding, pending completion of the Investigation; and (ii) there may be adjustments to the unaudited 2019 Annual Results, which, accumulated with those relating to the 2017 Annual Results and the 2018 Annual Results (which are yet to be ascertained), will render the unaudited 2019 Annual Results not being accurately and fairly reflecting the financial performance and position of the Company and its subsidiaries, and their publications may be potentially misleading and/or confusing to the shareholders and potential investors of the Company.

The Company will make further announcement(s) to inform the shareholders and potential investors of the Company on the publication of the 2019 Annual Results and the 2019 Annual Report as and when appropriate.

GENERAL

As disclosed in its announcement dated 31 January 2020, the Company had failed to meet the Resumption Conditions by 31 January 2020 and had made an application to the Stock Exchange for an extension of the resumption deadline.

Trading in the shares of the Company will continue to be suspended. The Company will update its shareholders and potential investors on any material development relating to the above as and when appropriate in compliance with the Listing Rules.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

For and on behalf of the Board of
China Wah Yan Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 31 March 2020

As at the date of this announcement, the board of directors of the Company comprises three executive directors, namely Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo; and four independent non-executive directors, namely, Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen, Mr. Lam Chun Ho and Mr. Tsang Hung Kei.